---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-179466"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:56.774030+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Kalaris Therapeutics stockholders elect two Class II directors, ratify Deloitte as auditor

## Summary
- Srinivas Akkaraju and Andrew Oxtoby elected as Class II directors for three-year terms expiring 2028.
- Akkaraju: 14,626,646 for, 144,695 withheld; Oxtoby: 14,668,424 for, 102,917 withheld.
- Ratification of Deloitte & Touche as independent auditor for FY2025 approved with 16,090,928 for, 6,975 against, 1,786 abstain.
- Broker non-votes of 1,328,348 on director elections due to routine matters.

## SEC filing metadata
- accession: 0001193125-25-179466
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525179466/0001193125-25-179466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525179466/d885835d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-179466
- JSON: https://secwatch.observer/filing/0001193125-25-179466.json
- Plain text: https://secwatch.observer/filing/0001193125-25-179466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.